Publications by authors named "Peter R Rhode"

Claim this Profile
T
TGF-βRII/IL-15 immunotherapeutic complex targets exhausted CD8 T-cell subsets in lymph nodes and tumors.
Varghese K George, Hing C Wong, Martin Felices, Mark P Rubinstein, Niraj Shrestha, Peter R Rhode

J Immunother Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of analytical methods for detection of anti-drug antibodies neutralizing IL-15 and TGF-β RII activity.
Gilles M Leclerc, Jack O Egan, Lijing You, Niraj Shrestha, Peter R Rhode

J Immunoassay Immunochem· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A "Prime and Expand" strategy using the multifunctional fusion proteins to generate memory-like NK cells for cell therapy.
Niraj Shrestha, Michael J Dee, Pallavi Chaturvedi, Gilles M Leclerc, Mary Mathyer, Peter R Rhode

Cancer Immunol Immunother· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapeutic approach to reduce senescent cells and alleviate senescence-associated secretory phenotype in mice.
Niraj Shrestha, Pallavi Chaturvedi, Xiaoyun Zhu, Michael J Dee, Varghese George, Peter R Rhode

Aging Cell· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel interleukin-2-based fusion molecule, HCW9302, differentially promotes regulatory T cell expansion to treat atherosclerosis in mice.
Xiaoyun Zhu, Qiongzhen Li, Varghese George, Catherine Spanoudis, Crystal Gilkes, Peter R Rhode

Front Immunol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapeutic HCW9218 augments anti-tumor activity of chemotherapy via NK cell-mediated reduction of therapy-induced senescent cells.
Pallavi Chaturvedi, Varghese George, Niraj Shrestha, Meng Wang, Michael J Dee, Peter R Rhode

Mol Ther· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bifunctional TGF-β trap/IL-15 protein complex elicits potent NK cell and CD8 T cell immunity against solid tumors.
Bai Liu, Xiaoyun Zhu, Lin Kong, Meng Wang, Catherine Spanoudis, Peter R Rhode

Mol Ther· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Fusion Protein Complex that Combines IL-12, IL-15, and IL-18 Signaling to Induce Memory-Like NK Cells for Cancer Immunotherapy.
Michelle K Becker-Hapak, Niraj Shrestha, Ethan McClain, Michael J Dee, Pallavi Chaturvedi, Peter R Rhode

Cancer Immunol Res· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors.
Kim Margolin, Chihiro Morishima, Vamsidhar Velcheti, Jeffrey S Miller, Sylvia M Lee, Peter R Rhode

Clin Cancer Res· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models.
Bai Liu, Monica Jones, Lin Kong, Terra Noel, Emily K Jeng, Peter R Rhode

Cytokine· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
John M Wrangle, Vamsidhar Velcheti, Manish R Patel, Elizabeth Garrett-Mayer, Elizabeth G Hill, Peter R Rhode

Lancet Oncol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses.
Bai Liu, Lin Kong, Kaiping Han, Hao Hong, Warren D Marcus, Peter R Rhode

J Biol Chem· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.
Maximillian Rosario, Bai Liu, Lin Kong, Lynne I Collins, Stephanie E Schneider, Peter R Rhode

Clin Cancer Res· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model.
Dimitrios Mathios, Chul-Kee Park, Warren D Marcus, Sarah Alter, Peter R Rhode

Int J Cancer· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models.
Peter R Rhode, Jack O Egan, Wenxin Xu, Hao Hong, Gabriela M Webb

Cancer Immunol Res· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion.
Evan Gomes-Giacoia, Makito Miyake, Steve Goodison, Aravindhan Sriharan, Ge Zhang, Peter R Rhode

PLoS One· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8 T cells into innate-like effector cells with antitumor activity.
Hing C Wong, Emily K Jeng, Peter R Rhode

Oncoimmunology· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor αSu/Fc fusion complex in syngeneic murine models of multiple myeloma.
Wenxin Xu, Monica Jones, Bai Liu, Xiaoyun Zhu, Christopher B Johnson, Peter R Rhode

Cancer Res· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study evaluating the pharmacokinetics, safety and tolerability of an antibody-based tissue factor antagonist in subjects with acute lung injury or acute respiratory distress syndrome.
Peter E Morris, Jay S Steingrub, Bee Y Huang, Shamay Tang, Patrick M Liu, Peter R Rhode

BMC Pulm Med· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies.
Mayer N Fishman, John A Thompson, Gregory K Pennock, Rene Gonzalez, Luz M Diez, Peter R Rhode

Clin Cancer Res· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization.
Kai-ping Han, Xiaoyun Zhu, Bai Liu, Emily Jeng, Lin Kong, Peter R Rhode

Cytokine· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin-15:Interleukin-15 receptor α scaffold for creation of multivalent targeted immune molecules.
Richard L Wong, Bai Liu, Xiaoyun Zhu, Lijing You, Lin Kong, Peter R Rhode

Protein Eng Des Sel· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of acute vascular thrombosis in chimpanzees by an anti-human tissue factor antibody targeting the factor X binding site.
Jin-an Jiao, Andrew B Kelly, Ulla M Marzec, Esperanza Nieves, Jorge Acevedo, Peter R Rhode

Thromb Haemost· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel human interleukin-15 agonists.
Xiaoyun Zhu, Warren D Marcus, Wenxin Xu, Hyung-il Lee, Kaiping Han, Peter R Rhode

J Immunol· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting activity of a TCR/IL-2 fusion protein against established tumors.
Jinghai Wen, Xiaoyun Zhu, Bai Liu, Lijing You, Lin Kong, Peter R Rhode

Cancer Immunol Immunother· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis